No connection

Search Results

CPHI

BEARISH
$0.63 Live
China Pharma Holdings, Inc. · AMEX
$0.5 52W Range $2.6

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 25, 2026
Market cap
$25.5M
P/E
N/A
ROE
-20.9%
Profit margin
-76.9%
Debt/Equity
0.17
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
CPHI exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a critical liquidity crisis. The company is operating with a negative gross margin (-3.18%), meaning it loses money on every product sold before operating expenses are even considered. With a current ratio of 0.32 and a quick ratio of 0.09, the firm lacks the liquid assets to cover its short-term obligations. This fundamental collapse is reflected in a catastrophic 5-year price decline of 99.8%.

Key Strengths

Low Debt/Equity ratio (0.17) suggests limited long-term leverage
Modest year-over-year revenue growth of 8.10%
Trading at a discount to book value (P/B 0.43)
Positive Q/Q revenue growth (8.11%)
Low PEG ratio (0.16) though misleading due to negative earnings

Key Risks

Critical liquidity risk with a Current Ratio of 0.32
Negative gross margins indicate a non-viable core business model
Severe profitability collapse (Operating Margin -97.86%)
Extreme price depreciation (-99.8% over 5 years)
Micro-cap volatility and total lack of institutional analyst coverage

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
10
Weak
Value
20
Future
15
Past
5
Health
10
Dividend
0
AI Verdict
Distressed Asset
Key drivers: Negative Gross Margins, Liquidity Crisis, Piotroski F-Score 2/9, Total Price Collapse
Confidence
95%
Value
20/100

P/B is low, but likely reflects impaired asset values given the operational losses.

Positives
  • P/B ratio of 0.43
Watchpoints
  • High P/S ratio (6.15) relative to negative margins
  • No positive earnings for Graham Number calculation
Future
15/100

Revenue growth is negligible compared to the scale of operating losses.

Positives
  • Slight revenue growth
Watchpoints
  • Negative ROE (-20.91%)
  • Negative ROA (-8.41%)
  • Unsustainable cost structure
Past
5/100

Long-term trend is a near-total loss of shareholder value.

Positives
No standout positives identified.
Watchpoints
  • 5Y Change: -99.8%
  • 1Y Change: -61.8%
  • Consistent earnings misses in historical data
Health
10/100

The company is facing an imminent liquidity crunch.

Positives
  • Low Debt/Equity
Watchpoints
  • Piotroski F-Score 2/9
  • Current Ratio 0.32
  • Quick Ratio 0.09
Dividend
0/100

Dividend strength is 0/100.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity for dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.63

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for CPHI and closest competitors.

Updated 2026-04-24
CPH
China Pharma Holdings, Inc.
Primary
5Y
-99.8%
3Y
-96.3%
1Y
-61.8%
6M
-65.4%
1M
-1.6%
1W
-6.0%
TXM
TherapeuticsMD, Inc.
Peer
5Y
-96.5%
3Y
-41.7%
1Y
+118.0%
6M
+86.3%
1M
-5.6%
1W
+3.3%
DAR
Daré Bioscience, Inc.
Peer
5Y
-91.0%
3Y
-85.0%
1Y
-38.6%
6M
-21.2%
1M
+15.7%
1W
-2.8%
LFW
Lifeward Ltd.
Peer
5Y
-96.0%
3Y
-88.2%
1Y
-60.6%
6M
-26.0%
1M
-1.6%
1W
-4.2%
ICC
IceCure Medical Ltd
Peer
5Y
-97.0%
3Y
-71.2%
1Y
-71.9%
6M
-62.9%
1M
-51.7%
1W
+7.7%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
0.16
P/B Ratio
0.43
P/S Ratio
6.15
EV/Revenue
7.01
EV/EBITDA
-18.34
Market Cap
$25.5M

Profitability

Profit margins and return metrics

Profit Margin -76.92%
Operating Margin -97.86%
Gross Margin -3.18%
ROE -20.91%
ROA -8.41%

Growth

Revenue and earnings growth rates

Revenue Growth +8.1%
Earnings Growth N/A
Q/Q Revenue Growth +8.11%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.17
Low debt
Current Ratio
0.32
Weak
Quick Ratio
0.09
Poor
Cash/Share
$0.01

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
12.3%
Op. Margin
-97.9%
Net Margin
-99.7%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.36x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
96%

Quarterly Earnings History

EPS performance vs analyst estimates

2011-11-10
$40.0
-33.3% surprise
2011-08-11
$55.35
+0.6% surprise
2011-05-11
$50.0
-13.0% surprise
2011-03-03
$95.0
+21.3% surprise

Healthcare Sector Comparison

Comparing CPHI against 537 companies in the Healthcare sector (28 bullish, 159 neutral, 350 bearish)
Return on Equity (ROE)
-20.91%
This Stock
vs
-91.87%
Sector Avg
-77.2% (Below Avg)
Profit Margin
-76.92%
This Stock
vs
-16.49%
Sector Avg
+366.5% (Superior)
Debt to Equity
0.17
This Stock
vs
2.73
Sector Avg
-93.7% (Less Debt)
Revenue Growth
8.1%
This Stock
vs
129.42%
Sector Avg
-93.7% (Slower)
Current Ratio
0.32
This Stock
vs
4.57
Sector Avg
-93.1% (Weaker)

Similar Companies

Peer comparison within the same industry

SEC Filings

Recent regulatory filings from the SEC EDGAR database

10-K
ANNUAL REPORT
2026-04-01

CPHI filed its 10-K annual report on April 1, 2026, which includes sections on business operations, risk factors, and management's discussion and analysis of financial condition. Specific financial highlights and risk details were not provided in the available excerpts.

8-K
CURRENT REPORT
2026-03-03

CPHI filed a current report on March 3, 2026, likely announcing annual financial results or a material corporate update.

8-K
CURRENT REPORT
2026-02-10

CPHI filed a current report on February 10, 2026, likely announcing its annual financial results for the preceding fiscal year.

8-K
CURRENT REPORT
2026-01-06

CPHI filed a current report on January 6, 2026, likely announcing year-end financial results or a material corporate update.

8-K
FORM 8-K
2025-12-23
8-K
CURRENT REPORT
2025-12-10
DEF 14A
DEFINITIVE PROXY STATEMENT
2025-11-14

CPHI filed a Definitive Proxy Statement (DEF 14A) on November 14, 2025, providing shareholders with necessary information to vote on corporate matters.

10-Q
QUARTERLY REPORT
2025-11-12

CPHI filed its Form 10-Q quarterly report on November 12, 2025. Due to the limited information provided, specific financial highlights and risk factors are not available for summary.

10-Q
QUARTERLY REPORT
2025-08-14

CPHI filed its Form 10-Q quarterly report on August 14, 2025. Due to the absence of provided excerpts, specific financial highlights and risk factors are not available for analysis.

10-Q
QUARTERLY REPORT
2025-05-14

CPHI filed its Form 10-Q quarterly report on May 14, 2025. Due to the absence of provided excerpts, specific financial highlights and risk factors are not available for analysis.

8-K
CURRENT REPORT
2025-04-04
10-K
ANNUAL REPORT
2025-03-31
8-K
CURRENT REPORT
2024-12-26
8-K
CURRENT REPORT
2024-12-26
8-K
CURRENT REPORT
2024-12-13
Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning CPHI from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI Chat
Markets
Profile